Close Menu

MDxHealth

Enzo Biochem and its subsidiary Enzo Life Sciences announced this week that the Patent Trial and Appeal Board has denied a petition filed by Hologic for inter partes review, a procedure for challenging the validity of patent claims, against US Patent 6,221,581.

The firm said total test volumes rose 55 percent during the quarter, and test volumes for its SelectMDx liquid biopsy test nearly tripled in Europe.

A brief recap of Diagnostics news the week of Apr 20, 2018: Boston Scientific, Interpace, Human Longevity, CareDX, OpGen SeraCare Life Sciences, Omega Diagnostics, MDxHealth's SelectMDx.

The companies will co-fund a new study of the 3DS technology, and MDxHealth will have the option to exclusively license the telomere-based test.

The Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata research hospital in Rome will perform SelectMDx testing locally.

Excluding the sale of the company's colorectal cancer patents to Exact Sciences, its 2017 revenues rose 13 percent.

UgenTec will develop artificially intelligent software to support interpretation of MDxHealth's ConfirMDx and SelectMDx molecular prostate cancer tests.

The company expects to see lower growth in products and services due to timing issues in obtaining billable cases from contracted customers.

Under the terms of the five-year deal, pharmaceutical company Ferrer will sell SelectMDx test directly to urologists in Spain.

Excluding revenues from the sale of MDxHealth's colorectal cancer patents to Exact Sciences, total revenues increased approximately 3 percent for the period.

Pages